{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:29:53Z","timestamp":1788834593697,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["150AV003\/CA2"],"award-info":[{"award-number":["150AV003\/CA2"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is an X-linked progressive muscle-wasting disorder that is caused by a lack of functional dystrophin, a cytoplasmic protein necessary for the structural integrity of muscle. As variants in the dystrophin gene lead to a disruption of the reading frame, pharmacological treatments have only limited efficacy; there is currently no effective therapy and consequently, a significant unmet clinical need for DMD. Recently, novel genetic approaches have shown real promise in treating DMD, with advancements in the efficacy and tropism of exon skipping and surrogate gene therapy. CRISPR-Cas9 has the potential to be a \u2018one-hit\u2019 curative treatment in the coming decade. The current limitations of gene editing, such as off-target effects and immunogenicity, are in fact partly constraints of the delivery method itself, and thus research focus has shifted to improving the viral vector. In order to halt the loss of ambulation, early diagnosis and treatment will be pivotal. In an era where genetic sequencing is increasingly utilised in the clinic, genetic therapies will play a progressively central role in DMD therapy. This review delineates the relative merits of cutting-edge genetic approaches, as well as the challenges that still need to be overcome before they become clinically viable.<\/jats:p>","DOI":"10.1038\/s41431-021-00811-2","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T20:43:29Z","timestamp":1612903409000},"page":"1369-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-5317","authenticated-orcid":false,"given":"Vratko","family":"Himi\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-8520","authenticated-orcid":false,"given":"Kay E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen G-JB, Kunkel LM. The pathogenesis and therapy of muscular dystrophies. Annu Rev Genomics Hum Genet. 2015;16:281\u2013308.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"811_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15:373\u201386.","journal-title":"Nat Rev Neurol"},{"key":"811_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/17460441.2020.1718100","volume":"15","author":"NB Wasala","year":"2020","unstructured":"Wasala NB, Chen S-J, Duan D. Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine. Expert Opin Drug Discov 2020;15:443\u201356.","journal-title":"Expert Opin Drug Discov"},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/hmg\/ddy171","volume":"27","author":"L Echevarr\u00eda","year":"2018","unstructured":"Echevarr\u00eda L, Aupy P, Lie Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018;27:163\u201372.","journal-title":"Hum Mol Genet."},{"key":"811_CR5","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, et al. Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther. 2017;27:251\u20139.","DOI":"10.1089\/nat.2017.0682"},{"key":"811_CR6","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study. Sarepta Therapeutics, Inc. 2019. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-positive-expression-results."},{"key":"811_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des, Dev Ther. 2017;11:533\u201345.","journal-title":"Drug Des, Dev Ther."},{"key":"811_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines6010001","volume":"6","author":"T Aslesh","year":"2018","unstructured":"Aslesh T, Maruyama R, Yokota T. Skipping multiple exons to treat DMD-promises and challenges. Biomedicines. 2018;6:1.","journal-title":"Biomedicines"},{"key":"811_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","volume":"27","author":"KRQ Lim","year":"2019","unstructured":"Lim KRQ, Echigoya Y, Nagata T, Kuraoka M, Kobayashi M, Aoki Y, et al. Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates. Mol Ther. 2019;27:76\u201386.","journal-title":"Mol Ther"},{"key":"811_CR10","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","volume":"27","author":"Y Echigoya","year":"2019","unstructured":"Echigoya Y, Lim KRQ, Melo D, Bao B, Trieu N, Mizobe Y, et al. Exons 45\u201355 skipping using mutation-tailored cocktails of antisense morpholinos in the DMD gene. Mol Ther. 2019;27:2005\u201317.","journal-title":"Mol Ther"},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"e0197084","DOI":"10.1371\/journal.pone.0197084","volume":"13","author":"J Lee","year":"2018","unstructured":"Lee J, Echigoya Y, Duddy W, Saito T, Aoki Y, Takeda S, et al. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS ONE. 2018;13:e0197084.","journal-title":"PLoS ONE"},{"key":"811_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jpm8040041","volume":"8","author":"Y Echigoya","year":"2018","unstructured":"Echigoya Y, Lim KRQ, Nakamura A, Yokota T. Multiple exon skipping in the Duchenne muscular dystrophy hot spots: prospects and challenges. J Pers Med. 2018;8:41.","journal-title":"J Pers Med"},{"key":"811_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/hum.2012.234","volume":"24","author":"T Koo","year":"2013","unstructured":"Koo T, Wood MJ. Clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy. Hum Gene Ther Hum Gene Ther. 2013;24:479\u201388.","journal-title":"Hum Gene Ther Hum Gene Ther"},{"key":"811_CR14","doi-asserted-by":"crossref","unstructured":"Tsoumpra MK, Fukumoto S, Matsumoto T, Takeda S, Wood MJA, Aoki Y. Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine. 2019;45:630\u201345.","DOI":"10.1016\/j.ebiom.2019.06.036"},{"key":"811_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymthe.2017.10.004","volume":"26","author":"SMG Jirka","year":"2018","unstructured":"Jirka SMG, \u2019t Hoen PAC, Diaz Parillas V, Tanganyika-de Winter CL, Verheul RC, Aguilera B, et al. Cyclic peptides to improve delivery and exon skipping of antisense oligonucleotides in a mouse model for Duchenne muscular dystrophy. Mol Ther. 2018;26:132\u201347.","journal-title":"Mol Ther."},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KRQ, Trieu N, et al. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2017;114:4213\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"811_CR17","unstructured":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients with Duchenne Muscular Dystrophy (DMD)\u2014NCT03375255. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03375255."},{"key":"811_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","volume":"8","author":"K Relizani","year":"2017","unstructured":"Relizani K, Griffith G, Echevarr\u00eda L, Zarrouki F, Facchinetti P, Vaillend C, et al. Efficacy and safety profile of Tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model. Mol Ther Nucleic Acids. 2017;8:144\u201357.","journal-title":"Mol Ther Nucleic Acids"},{"key":"811_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1152\/jn.00248.2016","volume":"116","author":"MG Rae","year":"2016","unstructured":"Rae MG, O\u2019Malley D. Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules. J Neurophysiol Am Physiological Soc. 2016;116:1304\u201315.","journal-title":"J Neurophysiol Am Physiological Soc"},{"key":"811_CR20","unstructured":"Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy\u2014NCT03907072. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03907072."},{"key":"811_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/jpm8040038","volume":"8","author":"KRQ Lim","year":"2018","unstructured":"Lim KRQ, Yoon C, Yokota T. Applications of CRISPR\/Cas9 for the treatment of duchenne muscular dystrophy. J Pers Med. 2018;8:38.","journal-title":"J Pers Med"},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"eaav4324","DOI":"10.1126\/sciadv.aav4324","volume":"5","author":"Y-L Min","year":"2019","unstructured":"Min Y-L, Li H, Rodriguez-Caycedo C, Mireault AA, Huang J, Shelton JM, et al. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci Adv. 2019;5:eaav4324.","journal-title":"Sci Adv"},{"key":"811_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403\u20137.","journal-title":"Science"},{"key":"811_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","volume":"26","author":"A Moretti","year":"2020","unstructured":"Moretti A, Fonteyne L, Giesert F, Hoppmann P, Meier AB, Bozoglu T, et al. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med Nat Res. 2020;26:207\u201314.","journal-title":"Nat Med Nat Res"},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause duchenne muscular dystrophy. Nat Commun. 2015;6:1\u201313.","journal-title":"Nat Commun"},{"key":"811_CR26","doi-asserted-by":"publisher","first-page":"e95918","DOI":"10.1172\/jci.insight.95918","volume":"2","author":"V Kyrychenko","year":"2017","unstructured":"Kyrychenko V, Kyrychenko S, Tiburcy M, Shelton JM, Long C, Schneider JW, et al. Functional correction of dystrophin actin binding domain mutations by genome editing. JCI Insight. 2017;2:e95918.","journal-title":"JCI Insight"},{"key":"811_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017;8:14454.","journal-title":"Nat Commun"},{"key":"811_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","volume":"25","author":"CE Nelson","year":"2019","unstructured":"Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25:427\u201332.","journal-title":"Nat Med"},{"key":"811_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41434-019-0119-y","volume":"27","author":"I Maggio","year":"2020","unstructured":"Maggio I, Zittersteijn HA, Wang Q, Liu J, Janssen JM, Ojeda IT, et al. Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components. Gene Ther. 2020;27:209\u201325.","journal-title":"Gene Ther"},{"key":"811_CR30","doi-asserted-by":"publisher","first-page":"8693","DOI":"10.1073\/pnas.1820523116","volume":"116","author":"D Zhang","year":"2019","unstructured":"Zhang D, Hurst T, Duan D, Chen SJ. Unified energetics analysis unravels SpCas9 cleavage activity for optimal gRNA design. Proc Natl Acad Sci USA. 2019;116:8693\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"811_CR31","doi-asserted-by":"crossref","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25:249\u201354.","DOI":"10.1038\/s41591-018-0326-x"},{"key":"811_CR32","doi-asserted-by":"crossref","unstructured":"Wagner DL, Amini L, Wendering DJ, Burkhardt LM, Aky\u00fcz L, Reinke P, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med. 2019;25:242\u20138.","DOI":"10.1038\/s41591-018-0204-6"},{"key":"811_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1101\/gr.231936.117","volume":"28","author":"S Kim","year":"2018","unstructured":"Kim S, Koo T, Jee HG, Cho HY, Lee G, Lim DG, et al. CRISPR RNAs trigger innate immune responses in human cells. Genome Res. 2018;28:367\u201373.","journal-title":"Genome Res"},{"key":"811_CR34","doi-asserted-by":"publisher","first-page":"e124297","DOI":"10.1172\/jci.insight.124297","volume":"3","author":"CH Hakim","year":"2018","unstructured":"Hakim CH, Wasala NB, Nelson CE, Wasala LP, Yue Y, Louderman JA, et al. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. JCI Insight. 2018;3:e124297.","journal-title":"JCI Insight"},{"key":"811_CR35","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365.","journal-title":"Science"},{"key":"811_CR36","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ymthe.2019.06.012","volume":"27","author":"ME Nance","year":"2019","unstructured":"Nance ME, Shi R, Hakim CH, Wasala NB, Yue Y, Pan X, et al. AAV9 edits muscle stem cells in normal and dystrophic adult mice. Mol Ther. 2019;27:1568\u201385.","journal-title":"Mol Ther"},{"key":"811_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41592-019-0323-0","volume":"16","author":"D Katrekar","year":"2019","unstructured":"Katrekar D, Chen G, Meluzzi D, Ganesh A, Worlikar A, Shih YR, et al. In vivo RNA editing of point mutations via RNA-guided adenosine deaminases. Nat Methods. 2019;16:239\u201342.","journal-title":"Nat Methods"},{"key":"811_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41592-018-0017-z","volume":"15","author":"P Vogel","year":"2018","unstructured":"Vogel P, Moschref M, Li Q, Merkle T, Selvasaravanan KD, Li JB, et al. Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs. Nat Methods. 2018;15:535\u20138.","journal-title":"Nat Methods"},{"key":"811_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1126\/science.aax7063","volume":"365","author":"OO Abudayyeh","year":"2019","unstructured":"Abudayyeh OO, Gootenberg JS, Franklin B, Koob J, Kellner MJ, Ladha A, et al. A cytosine deaminase for programmable single-base RNA editing. Science. 2019;365:382\u20136.","journal-title":"Science"},{"key":"811_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41598-017-00152-5","volume":"7","author":"JR Counsell","year":"2017","unstructured":"Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, et al. Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep. 2017;7:79.","journal-title":"Sci Rep."},{"key":"811_CR41","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/s41591-019-0604-2","volume":"25","author":"KE Davies","year":"2019","unstructured":"Davies KE, Chamberlain JS. Surrogate gene therapy for muscular dystrophy. Nat Med 2019;25:1473\u20134.","journal-title":"Nat Med"},{"key":"811_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:1\u201315.","journal-title":"Nat Commun"},{"key":"811_CR43","unstructured":"Sarepta Therapeutics Announces Positive Updated Results from Micro-dystrophin Trial to Treat Patients with DMD. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-23rd-international-congress-world."},{"key":"811_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","volume":"27","author":"JN Ramos","year":"2019","unstructured":"Ramos JN, Hollinger K, Bengtsson NE, Allen JM, Hauschka SD, Chamberlain JS. Development of novel micro-dystrophins with enhanced functionality. Mol Ther. 2019;27:623\u201335.","journal-title":"Mol Ther"},{"key":"811_CR45","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Morales L, Malik AS, Mead AF, Greer CD, Mitchell MA, et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat Med. 2019;25:1505\u201311.","journal-title":"Nat Med"},{"key":"811_CR46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","volume":"27","author":"R Xu","year":"2019","unstructured":"Xu R, Jia Y, Zygmunt DA, Martin PT. rAAVrh74.MCK.GALGT2 protects against loss of hemodynamic function in the aging mdx mouse heart. Mol Ther. 2019;27:636\u201349.","journal-title":"Mol Ther"},{"key":"811_CR47","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","volume":"22","author":"LG Chicoine","year":"2014","unstructured":"Chicoine LG, Rodino-Klapac LR, Shao G, Xu R, Bremer WG, Camboni M, et al. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates. Mol Ther. 2014;22:713\u201324.","journal-title":"Mol Ther."},{"key":"811_CR48","unstructured":"Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy\u2014NCT03333590. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03333590."},{"key":"811_CR49","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41467-017-01146-7","volume":"8","author":"A Voit","year":"2017","unstructured":"Voit A, Patel V, Pachon R, Shah V, Bakhutma M, Kohlbrenner E, et al. Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice. Nat Commun. 2017;8:1068.","journal-title":"Nat Commun"},{"key":"811_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ymthe.2019.12.011","volume":"28","author":"NB Wasala","year":"2020","unstructured":"Wasala NB, Yue Y, Lostal W, Wasala LP, Niranjan N, Hajjar RJ, et al. Single SERCA2a therapy ameliorated dilated cardiomyopathy for 18 months in a mouse model of Duchenne muscular dystrophy. Mol Ther. 2020;28:845\u201354.","journal-title":"Mol Ther"},{"key":"811_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet Nat Res. 2020;21:255\u201372.","journal-title":"Nat Rev Genet Nat Res"},{"key":"811_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28:723\u201346.","journal-title":"Mol Ther"},{"key":"811_CR53","doi-asserted-by":"publisher","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","volume":"6","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Li H, Min YL, Sanchez-Ortiz E, Huang J, Mireault AA, et al. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system. Sci Adv. 2020;6:eaay6812.","journal-title":"Sci Adv"},{"key":"811_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14957-y","volume":"11","author":"P Gee","year":"2020","unstructured":"Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun. 2020;11:1334.","journal-title":"Nat Commun"},{"key":"811_CR55","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","volume":"1","author":"K Lee","year":"2017","unstructured":"Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng. 2017;1:889\u2013901.","journal-title":"Nat Biomed Eng"},{"key":"811_CR56","unstructured":"CHMP. Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report\u2014Exondys, eteplirsen. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exondys."},{"key":"811_CR57","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1038\/mtna.2014.6","volume":"3","author":"QL Lu","year":"2014","unstructured":"Lu QL, Cirak S, Partridge T. What can we learn from clinical trials of exon skipping for DMD? Mol Ther Nucleic Acids. 2014;3:e152.","journal-title":"Mol Ther Nucleic Acids"},{"key":"811_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JND-180357","volume":"6","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus A, Morgan J, Lonkar P, Neubert H, Owens J, Binks M, et al. Report of a TREAT-NMD\/World duchenne organisation meeting on dystrophin quantification methodology. J Neuromuscul Dis. 2019;6:147\u201359.","journal-title":"J Neuromuscul Dis"},{"key":"811_CR59","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/jcsm.12304","volume":"9","author":"P Spitali","year":"2018","unstructured":"Spitali P, Hettne K, Tsonaka R, Charrout M, van den Bergen J, Koeks Z, et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. J Cachexia Sarcopenia Muscle. 2018;9:715\u201326.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"811_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaneurol.2019.1206","volume":"76","author":"M Baker","year":"2019","unstructured":"Baker M, Griggs R, Byrne B, Connolly AM, Finkel R, Grajkowska L, et al. Maximizing the benefit of life-saving treatments for pompe disease, spinal muscular atrophy, and Duchenne muscular dystrophy through newborn screening: essential steps. JAMA Neurol Am Med Assoc. 2019;76:978\u201383.","journal-title":"JAMA Neurol Am Med Assoc"},{"key":"811_CR61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fgene.2018.00114","volume":"9","author":"G Cordova","year":"2018","unstructured":"Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C. Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy. Front Genet. 2018;9:114.","journal-title":"Front Genet"},{"key":"811_CR62","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/hmg\/ddz049","volume":"28","author":"S Guiraud","year":"2019","unstructured":"Guiraud S, Edwards B, Babbs A, Squire SE, Berg A, Moir L, et al. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Hum Mol Genet. 2019;28:2189\u2013200.","journal-title":"Hum Mol Genet"},{"key":"811_CR63","doi-asserted-by":"crossref","unstructured":"Barth\u00e9l\u00e9my F, Wein N. Personalized gene and cell therapy for Duchenne muscular dystrophy. Neuromuscular Disorders. 2018;28:803\u201324.","DOI":"10.1016\/j.nmd.2018.06.009"},{"key":"811_CR64","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41431-019-0563-6","volume":"28","author":"P Spitali","year":"2020","unstructured":"Spitali P, Zaharieva I, Bohringer S, Hiller M, Chaouch A, Roos A, et al. TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. Eur J Hum Genet. 2020;28:815\u201325.","journal-title":"Eur J Hum Genet"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-00811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-00811-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-00811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T23:29:58Z","timestamp":1631662198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-00811-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1038\/s41431-021-00811-2","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"23 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}